137 related articles for article (PubMed ID: 38110323)
1. Clinicopathological analysis of CD47 and signal regulatory protein alpha expression in myeloid sarcoma patients: CD47 expression is a favourable prognostic factor.
Tanaka K; Miyoshi H; Kawamoto K; Shimasaki Y; Nakashima K; Imamoto T; Yamada K; Takeuchi M; Moritsubo M; Furuta T; Kohno K; Tamura S; Sonoki T; Ohshima K
Pathology; 2024 Feb; 56(1):81-91. PubMed ID: 38110323
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological analysis of immunohistochemical expression of CD47 and SIRPα in adult T-cell leukemia/lymphoma.
Yanagida E; Miyoshi H; Takeuchi M; Yoshida N; Nakashima K; Yamada K; Umeno T; Shimasaki Y; Furuta T; Seto M; Ohshima K
Hematol Oncol; 2020 Dec; 38(5):680-688. PubMed ID: 32569413
[TBL] [Abstract][Full Text] [Related]
3. Combination of CD47 and signal-regulatory protein-α constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma.
Kazama R; Miyoshi H; Takeuchi M; Miyawaki K; Nakashima K; Yoshida N; Kawamoto K; Yanagida E; Yamada K; Umeno T; Suzuki T; Kato K; Takizawa J; Seto M; Akashi K; Ohshima K
Cancer Sci; 2020 Jul; 111(7):2608-2619. PubMed ID: 32342603
[TBL] [Abstract][Full Text] [Related]
4. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
[TBL] [Abstract][Full Text] [Related]
5. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
[TBL] [Abstract][Full Text] [Related]
6. Engagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cells.
Irandoust M; Alvarez Zarate J; Hubeek I; van Beek EM; Schornagel K; Broekhuizen AJ; Akyuz M; van de Loosdrecht AA; Delwel R; Valk PJ; Sonneveld E; Kearns P; Creutzig U; Reinhardt D; de Bont ES; Coenen EA; van den Heuvel-Eibrink MM; Zwaan CM; Kaspers GJ; Cloos J; van den Berg TK
PLoS One; 2013; 8(1):e52143. PubMed ID: 23320069
[TBL] [Abstract][Full Text] [Related]
7. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target.
Barclay AN; Van den Berg TK
Annu Rev Immunol; 2014; 32():25-50. PubMed ID: 24215318
[TBL] [Abstract][Full Text] [Related]
8. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
Ponce LP; Fenn NC; Moritz N; Krupka C; Kozik JH; Lauber K; Subklewe M; Hopfner KP
Oncotarget; 2017 Feb; 8(7):11284-11301. PubMed ID: 28061465
[TBL] [Abstract][Full Text] [Related]
9. Imaging of Glioblastoma Tumor-Associated Myeloid Cells Using Nanobodies Targeting Signal Regulatory Protein Alpha.
De Vlaminck K; Romão E; Puttemans J; Pombo Antunes AR; Kancheva D; Scheyltjens I; Van Ginderachter JA; Muyldermans S; Devoogdt N; Movahedi K; Raes G
Front Immunol; 2021; 12():777524. PubMed ID: 34917090
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in the human inhibitory signal-regulatory protein α do not affect binding to its ligand CD47.
Hatherley D; Lea SM; Johnson S; Barclay AN
J Biol Chem; 2014 Apr; 289(14):10024-8. PubMed ID: 24550402
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of signal regulatory protein alpha (SIRPα) expression in esophageal squamous cell carcinoma.
Koga N; Hu Q; Sakai A; Takada K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Oki E; Oda Y; Mori M
Cancer Sci; 2021 Aug; 112(8):3018-3028. PubMed ID: 34009732
[TBL] [Abstract][Full Text] [Related]
12. The regulation of CD47-SIRPα signaling axis by microRNAs in combination with conventional cytotoxic drugs together with the help of nano-delivery: a choice for therapy?
Beizavi Z; Gheibihayat SM; Moghadasian H; Zare H; Yeganeh BS; Askari H; Vakili S; Tajbakhsh A; Savardashtaki A
Mol Biol Rep; 2021 Jul; 48(7):5707-5722. PubMed ID: 34275112
[TBL] [Abstract][Full Text] [Related]
13. A homogeneous SIRPα-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology.
Burgess TL; Amason JD; Rubin JS; Duveau DY; Lamy L; Roberts DD; Farrell CL; Inglese J; Thomas CJ; Miller TW
PLoS One; 2020; 15(4):e0226661. PubMed ID: 32240171
[TBL] [Abstract][Full Text] [Related]
14. Lack of CD47 impairs bone cell differentiation and results in an osteopenic phenotype in vivo due to impaired signal regulatory protein α (SIRPα) signaling.
Koskinen C; Persson E; Baldock P; Stenberg Å; Boström I; Matozaki T; Oldenborg PA; Lundberg P
J Biol Chem; 2013 Oct; 288(41):29333-44. PubMed ID: 23990469
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances of Tumor Therapy Based on the CD47-SIRPα Axis.
Wang Y; Zhao C; Liu Y; Wang C; Jiang H; Hu Y; Wu J
Mol Pharm; 2022 May; 19(5):1273-1293. PubMed ID: 35436123
[TBL] [Abstract][Full Text] [Related]
16. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
17. Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts.
Theocharides AP; Jin L; Cheng PY; Prasolava TK; Malko AV; Ho JM; Poeppl AG; van Rooijen N; Minden MD; Danska JS; Dick JE; Wang JC
J Exp Med; 2012 Sep; 209(10):1883-99. PubMed ID: 22945919
[TBL] [Abstract][Full Text] [Related]
18. TSP1-CD47-SIRPα signaling facilitates the development of endometriosis by mediating the survival of ectopic endometrium.
Liu Y; Li M; Wei C; Tang L; Sheng Y; Liu Y; Li D; Ding D; Qiu J; Zhu X
Am J Reprod Immunol; 2020 Jun; 83(6):e13236. PubMed ID: 32196807
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
20. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
